Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma

NCT05661955 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05661955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05661955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study Investigating the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Urothelial Carcinoma, Renal Cell Carcinoma, or Melanoma
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 9, 2023
Completion date
October 31, 2026
Enrollment
113 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-mucosal melanoma, renal cell carcinoma, urothelial carcinoma